Module

Understanding HIV Entry and Targets for Therapy

Source: HIV Entry and Tropism: New Strategies for Effective Antiretroviral Therapy

Understanding HIV Entry and Targets for Therapy

Faculty:
Robert W. Doms, MD, PhD

CME CREDIT INFORMATION

Release Date: 10/11/07

Expiration Date: 10/10/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the mechanisms associated with HIV entry into the host cell
Identify steps in the viral entry process that represent targets for antiretroviral therapy
Discuss the mechanisms by which resistance to HIV entry inhibitors may occur

Topics covered include:

Introduction
Mechanisms of HIV Entry
Env Protein: The Viral Target for Entry Inhibitors
The Role of Receptor Binding in Viral Entry
CCR5 Antagonists: How Do They Work?
Challenges Associated With the Use of CCR5 Antagonists: Measuring Viral Tropism
Clinical Results—Maraviroc and Vicriviroc
Pathways of Viral Resistance With the Use of CCR5 Antagonists
Fusion Inhibitors
Summary and Future Directions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.